BR0213634A - Delayed-acting drug delivery system for an antispasmodic agent - Google Patents

Delayed-acting drug delivery system for an antispasmodic agent

Info

Publication number
BR0213634A
BR0213634A BR0213634-1A BR0213634A BR0213634A BR 0213634 A BR0213634 A BR 0213634A BR 0213634 A BR0213634 A BR 0213634A BR 0213634 A BR0213634 A BR 0213634A
Authority
BR
Brazil
Prior art keywords
delayed
delivery system
drug delivery
acting drug
antispasmodic agent
Prior art date
Application number
BR0213634-1A
Other languages
Portuguese (pt)
Inventor
Dilip Shantilal Shanghvi
Ashish Prabhakar Mungre
Yashoraj Rupsinh Zala
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IN2002/000107 external-priority patent/WO2002080887A2/en
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of BR0213634A publication Critical patent/BR0213634A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"SISTEMA DE LIBERAçãO DE DROGA COM AçãO RETARDADA PARA UM AGENTE ANTIESPASMóDICO". A presente invenção proporciona um sistema de liberação de droga com ação retardada para um agente antiespasmódico o qual compreende uma composição de liberação imediata e uma composição para a liberação em um pulso de ação retardada a qual libera quantidades pré-determinadas de oxibutinina como um pulso de início e em intervalos de tempo pré-determinados para proporcionar uma otimização da terapia. O sistema é adequado para a terapia de incontinência urinária a ser ministrada duas vezes por dia ou uma vez por dia."DELAYED ACTION DRUG RELEASE SYSTEM FOR AN ANPHASMODIC AGENT". The present invention provides a delayed acting drug release system for an antispasmodic agent which comprises an immediate release composition and a delayed release pulse composition which releases predetermined amounts of oxybutynin as a pulse. onset and at predetermined time intervals to provide optimal therapy. The system is suitable for urinary incontinence therapy to be given twice a day or once a day.

BR0213634-1A 2001-10-08 2002-10-08 Delayed-acting drug delivery system for an antispasmodic agent BR0213634A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN984MU2001 2001-10-08
PCT/IN2002/000107 WO2002080887A2 (en) 2001-04-10 2002-04-09 Timed pulse release composition
PCT/IN2002/000203 WO2003030920A1 (en) 2001-10-08 2002-10-08 An antispasmodic agent spaced drug delivery system

Publications (1)

Publication Number Publication Date
BR0213634A true BR0213634A (en) 2004-11-30

Family

ID=26324117

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0213634-1A BR0213634A (en) 2001-10-08 2002-10-08 Delayed-acting drug delivery system for an antispasmodic agent

Country Status (5)

Country Link
EP (1) EP1450783A1 (en)
JP (1) JP2005510477A (en)
CN (1) CN1564691A (en)
BR (1) BR0213634A (en)
WO (1) WO2003030920A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5159094B2 (en) * 2005-11-11 2013-03-06 旭化成ケミカルズ株式会社 Nucleated solid preparations that control the elution of active ingredients to be sustained release
PL2010158T3 (en) * 2006-04-26 2016-09-30 Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
EP2089002A1 (en) * 2006-10-13 2009-08-19 Janssen Pharmaceutica, N.V. Phenylalkyl carbamate compositions
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003766D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
CN1158071C (en) * 1997-05-30 2004-07-21 渗透有限公司 Multi-layered osmotic device
US6248359B1 (en) * 2000-01-05 2001-06-19 Laboratorios Phoenix U.S.A., Inc. Multi-tablet oxybutynin system for treating incontinence
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system

Also Published As

Publication number Publication date
CN1564691A (en) 2005-01-12
WO2003030920A1 (en) 2003-04-17
EP1450783A1 (en) 2004-09-01
JP2005510477A (en) 2005-04-21
WO2003030920A9 (en) 2003-06-26

Similar Documents

Publication Publication Date Title
HRP20050781B1 (en) Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
ATE340581T1 (en) METHOD FOR TREATING PROSTATE DISEASES USING DELAYED AND/OR EXTENDED RELEASE VITAMIN D FORMULATIONS
WO1996025947A3 (en) Induction of e-selectin for targetting therapeutic agents
BR0315304A (en) Depot formulations for controlled release
WO2008079404A3 (en) Pharmaceutical compositions for treatment of parkinson's disease and related disorders
MXPA03003354A (en) Coated medical devices for the treatment of vascular disease.
BR0317747A (en) Method of concomitant therapeutic treatment of an individual, pharmaceutical composition, kit, use of a first agent and a second agent, and methods of preventing or treating amyloid-b-related disease, alzheimer's disease and mild cognitive impairment
AR026610A1 (en) A PIRROLIDINACETAMIDE DERIVATIVE ONLY OR IN COMBINATION FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS
ATE343969T1 (en) COATED MEDICAL DEVICES
BRPI0609393B8 (en) uses of an 11-deoxy-prostaglandin compound
ATE228832T1 (en) SYSTEM FOR THE TARGETED DELIVERY OF ACTIVE INGREDIENTS, METHOD FOR THE PRODUCTION AND USE THEREOF
BRPI0407485A (en) use of anti-insulin-like growth factor i receptor antibodies
ATE267798T1 (en) COMBINED ACTIVE INGREDIENTS AS A METHOD FOR TARGETED ACTIVE RELEASE
PT752866E (en) MEDICINES FOR TREATING RESTENOSE BY COMPREHENDING POLYMERS THAT RELEASE NITRIC OXIDE
BR0210056A (en) compositions and methods for treating hyperplasia
BR0315580A (en) Methylene Urea Derivatives
CY1110078T1 (en) INJECTIONS WITH IODIDATED POVIDON FOR WASTE HEALING
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
BR9912179A (en) Neuroprotective composition for the prevention and / or treatment of nervous and behavioral changes due to states of anxiety or depression
DE60332363D1 (en) OLIGONUCLEOTIDES FOR THE TREATMENT OF PROSTATE CANCER AND OTHER CANCER DISEASES
YU30002A (en) Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
BRPI0411176A (en) pharmaceutical combination consisting of modafinil and another drug
BR0200246A (en) Combination treatment for depression
BR0313413A (en) Use of beta amyloid vaccination together with a selective cox-2 inhibitor for the treatment of alzheimer's disease
BR0310061A (en) Methods for treating respiratory diseases and conditions with a selective inhibitor of inos and a inhibitor of pde and their compositions

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 5O, 6O E 7O ANUIDADE.

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2034 DE 29/12/2009.

B15K Others concerning applications: alteration of classification

Ipc: A61K 31/221 (2006.01), A61P 11/06 (2006.01)